Crispr Therapeutics AG (NASDAQ:CRSP) insider Lawrence Otto Klein sold 20,000 shares of Crispr Therapeutics stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $50.02, for a total transaction of $1,000,400.00. Following the completion of the transaction, the insider now owns 31,579 shares in the company, valued at $1,579,581.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ CRSP traded down $0.07 during trading on Friday, hitting $49.11. 287,431 shares of the company were exchanged, compared to its average volume of 666,346. The stock has a market cap of $2.64 billion, a P/E ratio of -14.28 and a beta of 3.11. Crispr Therapeutics AG has a 1 year low of $22.22 and a 1 year high of $66.26. The stock has a fifty day moving average price of $42.99. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, April 29th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.03). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $1.50 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. Crispr Therapeutics’s revenue for the quarter was down 78.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) earnings per share. As a group, sell-side analysts forecast that Crispr Therapeutics AG will post -3.82 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Versant Venture Management LLC boosted its position in shares of Crispr Therapeutics by 17.7% during the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock worth $151,770,000 after purchasing an additional 640,014 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Crispr Therapeutics by 52.7% during the 1st quarter. ARK Investment Management LLC now owns 2,023,017 shares of the company’s stock worth $72,262,000 after purchasing an additional 697,907 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Crispr Therapeutics by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 509,572 shares of the company’s stock worth $14,558,000 after purchasing an additional 102,478 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Crispr Therapeutics by 14.5% during the 4th quarter. Two Sigma Advisers LP now owns 473,100 shares of the company’s stock worth $13,516,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Global Thematic Partners LLC boosted its position in shares of Crispr Therapeutics by 4.5% during the 1st quarter. Global Thematic Partners LLC now owns 468,525 shares of the company’s stock worth $16,735,000 after purchasing an additional 20,045 shares in the last quarter. Institutional investors own 48.96% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Portfolio Manager
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.